DO NOT COPY. Asthma is characterized by variable airflow obstruction,
|
|
- Meagan Ellis
- 6 years ago
- Views:
Transcription
1 Do inhaled corticosteroid/long-acting beta 2 -agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal Peter J. Barnes, M.D., 1 Gabriele Nicolini, Ph.D., 2 Andrea Bizzi, Pharm.D., 2 Monica Spinola, Ph.D., 2 and Dave Singh, M.D. 3 ABSTRACT Current asthma management guidelines emphasize the importance of disease control. Although effective drug therapies are available, real-life data indicate that the general level of asthma control is still low. Fixed-dose combinations of inhaled corticosteroids/long-acting beta 2 -agonists (ICS/LABAs) are now increasingly used in the management of asthma. A number of studies have compared the clinical benefits of ICS/LABA fixed combinations with the monocomponents administered using two separate inhalers. We conducted a database search to identify all published studies that have assessed whether fixed-dose combinations achieve greater asthma control compared with administration by separate inhalers. Among fixed combinations, only extrafine beclomethasone/formoterol provided significantly greater asthma control compared with separate inhalers administered as larger aerosol particles. This greater effect may be explained by increased delivery to the small airways by the extrafine formulation. (Allergy Asthma Proc 33: , 2012; doi: /aap ) Asthma is characterized by variable airflow obstruction, bronchial hyperresponsiveness, and airway inflammation. Asthma affects both the large and the small airways and there is growing evidence showing correlation between small airways impairment and poor asthma control. 1 Several randomized controlled trials have indicated that the addition of a long-acting 2 -agonist (LABA) is more beneficial in terms of improving asthma control and pulmonary function and reducing exacerbation rates compared with increasing the dose of inhaled corticosteroids (ICSs) in patients on low-to-medium doses of ICS. 2 6 ICS/LABA fixed-dose combinations are now increasingly used in asthma because they are more convenient for patients and the co-deposition of the two drugs can increase synergy at the molecular level. 7 A number of studies have compared the clinical benefits of ICS/LABA fixed combinations with From the 1 National Heart and Lung Institute, Imperial College, London, United Kingdom, 2 Chiesi Farmaceutici S.p.A., Parma, Italy, and 3 Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, University of Manchester, Manchester, United Kingdom PJ Barnes has served on Scientific Advisory Boards of AstraZeneca, Boehringer- Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Pfizer, Teva and UCB and has received research funding from AstraZeneca, Boehringer-Ingelheim, Chiesi, Daiichi-Sankyo, GlaxoSmithKline, Mistubishi-Tanabe, Novartis, and Pfizer. D Singh has received lectures fees, support for conference attendance, advisory board fees, and research grants from a range of pharmaceutical companies including GSK, Chiesi Pharmaceuticals, AstraZeneca, CIPLA, Novartis, Forest, MSD, Boehringer, and Allmiral. G Nicolini, A Bizzi, and M Spinola are full time employees of Chiesi Farmaceutici S.p.A. Address correspondence and reprint requests to Monica Spinola, Ph.D., Chiesi Farmaceutici S.p.A., via Palermo 26/A, 43122, Parma, Italy address: m.spinola@chiesigroup.com Copyright 2012, OceanSide Publications, Inc., U.S.A. the administration of the monocomponents using two separate inhalers. We performed a literature review of all published studies that have assessed whether fixed-dose combinations achieve greater asthma control compared with the monocomponents administered as separate inhalers. METHODS The Medline database was searched using the following terms: asthma control, fixed combination, separate inhalers, fluticasone salmeterol, budesonide formoterol, beclomethasone formoterol, and fluticasone formoterol. Searches were last updated on February Randomized controlled trials in asthma patients evaluating the effects of an ICS/LABA combination administered via a single inhaler compared with two separate inhalers were identified. The level of asthma control was assessed using different parameters in these studies. The most frequently used parameter was the percentage of asthma control days (defined as days without asthma symptoms, nocturnal awakenings, or rescue medication use). Other parameters included the proportion of days without asthma symptoms, the proportion of patients with 75% of days without asthma symptoms, and the Asthma Control Questionnaire (ACQ) score. 8 Data reported in the selected articles were extracted and used to calculate the increase in asthma control in fixed combinations when compared with separate inhalers. Percentage increase in asthma control (AC) was calculated as follows: 140 March April 2012, Vol. 33, No. 2
2 Table 1 Summary of randomized controlled trials comparing patients treated with ICS/LABA fixed combination or two separate inhalers Study AC increase (%) Patients No.; Age Baseline Mean FEV 1 (% predicted normal) (AC fixed combination AC separate components) AC separate components Duration (mo) Daily Dosage ( g) Fixed vs Separate Beclomethasone/formoterol Huchon et al ; 18 yr 65 6 extrafine 400/ 24 vs larger particles 1000/24 Fluticasone/salmeterol Bateman et al ; 12 yr /100 vs 200/100 Chapman et al ; 12 yr /100 vs 500/100 Aubier et al ; 12 yr /100 vs 1000/100 Budesonide/formoterol Zetterstrom et al ; 18 yr 74 3 vs Rosenhall et al ; 18 yr 95 6 vs Rosenhall et al. 15 # 321; 18 yr vs Jenkins et al ; 12 yr /48 vs 1600/48 Chervinsky et al ; 18 yr 68 3 vs Fluticasone/formoterol Bodzenta-Lukaszyk 620; 18 yr /40 vs et al /48 Measured Outcome Difference (fixed separate) AC days (%) 7.7* Patients with 75% symptom-free days (%) Patients with 75% symptom-free days (%) Symptom-free days (%) RESULTS Articles were available for all ICS/LABA fixed combinations used as key terms for a database search. The list of randomized controlled trials in patients with asthma comparing the effects of different ICS/LABA combinations administered via a single inhaler or two separate inhalers is presented in Table The studies using fluticasone/salmeterol used symptom-free days to assess AC. Studies of other fixed combination inhalers used either AC days or the ACQ score as an index of AC. The three studies of fluticasone/salmeterol showed that both the fixed combination inhaler and the separate inhalers increased the number of patients with 75% symptom-free days 10,11 and the percentage of symptom-free days versus baseline. 12 There was no significant difference between the treatment groups AC days (%) 1.6 ACQ score ACQ score 0 0 AC days (%) 0.2 AC days (%) 0.1 AC days (%) 0.6 *p #This study reports follow-up data of the study by Rosenhall et al. 14 Estimated from graph. AC asthma control; ACQ asthma control questionnaire; FEV 1 forced expiratory volume in 1 s; ICS/LABA inhaled corticosteroid/long-acting 2 -agonist. Allergy and Asthma Proceedings 141
3 Studies using budesonide/formoterol (F) showed similar improvements in the percentage of AC days observed in the fixed combination and separate inhaler groups. 13,16,17 Similarly, both the fixed combination and the separate inhalers provided a comparable decrease in the ACQ score at 6 and 12 months. 14,15 Jenkins et al. showed a trend toward a lower risk of mild exacerbations in the fixed combination inhaler versus the separate inhaler group (p 0.13). 16 Bodzenta-Lukaszyk et al. studied fluticasone/f and found that both the fixed combination and the separate inhalers provided a similar increase in AC days versus baseline, with no significant difference between treatments. 18 Huchon et al. studied extrafine beclomethasone/f and found that the fixed combination provided significantly greater AC compared with separate inhalers. 9 It should be noted that the beclomethasone and F separate inhalers delivered larger particle sizes, and that the ICS dose was greater in the separate treatment compared with the fixed treatment (1000 g versus 400 g, respectively). A post hoc analysis showed that combination therapy results in a 50.0% increase in the percentage of days with AC, which increased from 15.4% with separate inhalers to 23.0% with combination therapy (p 0.005; Fig. 1). 9 DISCUSSION AND CONCLUSIONS ICSs are the mainstay for anti-inflammatory therapy for patients with persistent asthma. Several randomized controlled trials have shown that addition of a LABA is more beneficial in terms of AC and pulmonary function than increasing the dose of corticosteroids in patients not fully controlled on lowto-medium doses of ICS. 2 6 Although the clinical benefits of combined ICS plus LABA therapy can be achieved with separate inhalers, fixed combination Figure 1. Asthma control changes in fixed combinations versus separate components. Percentage increase was calculated as described in the Materials and Methods section. Asthma control was defined in each study as detailed in Table 1. inhalers are more convenient for patients and they are likely to increase adherence to therapy by reducing the number of inhalers that patients need to take. Additionally, given the potential risks associated with the use of LABAs without an inhaled steroid, 19 fixed inhalers would reduce the concern about patients using LABAs only and ensure continuation of ICS therapy. A meta-analysis showed that the fluticasone/salmeterol fixed combination had a greater effect on morning peak expiratory flow compared with separate component inhalers (difference 5.4 l/min; p 0.006). 20 However, this small difference in lung function did not translate into symptomatic benefits in terms of the number of symptom-free and relieverfree days and nights. Such data question whether fixed combinations have clinically important benefits in terms of symptom control compared with separates. We therefore performed a systematic literature review to assess whether fixed-dose combinations achieve greater AC than separate inhalers. Studies were found for the ICS/LABA fixed combinations fluticasone/salmeterol, budesonide/f, beclomethasone/f, and fluticasone/f. There was a statistically significant improvement in AC only for the fixed combination of extrafine beclomethasone/f compared with its separate components. For the other fixed combinations, there were no differences compared with separates. Extrafine beclomethasone/f was administered using less than one-half the steroid dose of the separate ICS inhaler (400 g versus 1000 g, respectively). The key difference was the small particle size of the beclomethasone/f combination, allowing increased drug delivery to the distal airways compared with the larger particle size of the ICS separate inhaler. The extrafine formula- 142 March April 2012, Vol. 33, No. 2
4 tion of the fixed combination allows more particles to reach and treat the small airways, and this may result in greater clinical benefit when compared with larger particles. Another fixed combination is currently being developed that contains mometasone furoate (MF) and F. Recent studies have shown that MF/F is superior to mometasone alone or F alone in improving AC and reducing nocturnal symptoms However, no data are available comparing MF/F versus its two monocomponents administered concurrently via two separate inhalers. Additional studies are warranted to understand whether AC is different when administering MF and F with a single inhaler or two separates. It has been reported that AC correlates better with measurements of small airway function than with conventional spirometric indices. 1 The role of small airways in asthma pathogenesis is recognized and there is growing evidence that airway obstruction and inflammatory processes affect both large and small airways. 27,28 The data from Huchon et al. indicate that a significant clinical benefit can be gained by the use of extrafine formulations that target the small airways. 9 Jenkins et al. found no difference in the number of AC days when budesonide/f was administered as a fixed combination compared with separate inhalers, but there was a trend toward reduction in exacerbations using the combination inhaler. 16 This highlights that results may vary between asthma end points, as was the case for the meta-analysis of the fluticasone/salmeterol fixed combination, which had a greater effect on morning peak expiratory flow compared with separate inhalers but no benefit in terms of symptoms. In conclusion, this literature review has found that combination and separate inhaler therapy delivered as non extrafine particles are equivalent in terms of AC. In contrast, the small particle delivery of beclomethasone/f as a fixed combination provides significantly greater AC than separate inhalers that deliver larger particles with less delivery to the small airways. REFERENCES 1. Takeda T, Oga T, Niimi A,. Relationship between small airway function and health status, dyspnea, and disease control in asthma. Respiration 80: , Greening AP, Ind PW, Northfield M, and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344: , Woolcock A, Lundback B, Ringdal N, and Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153: , Matz J, Emmett A, Rickard K, and Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 107: , Shrewsbury S, Pyke S, and Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 320: , Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337: , Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 29: , Juniper EF, O Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 14: , Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 103:41 49, Bateman ED, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler: A new, effective and well tolerated treatment for asthma. Clin Drug Investig 16: , Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers. Can Respir J 6:45 51, Aubier M, Pieters WR, Schlösser NJ, and Steinmetz KO. Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93: , Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18: , Rosenhall L, Heinig JH, Lindqvist A, et al. Budesonide/ formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract 56: , Rosenhall L, Elvstrand A, Tilling B, et al. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respir Med 97: , Jenkins C, Kolarikova R, Kuna P, et al. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 11: , Chervinsky P, Baker J, Bensch G, et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol 101: , Bodzenta-Lukaszyk A, Pulka G, Dymek A, et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 105: , Chowdhury BA, and Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 362: , Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 112:29 36, Nicolini G, Scichilone N, Bizzi A, et al. Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations. Ther Clin Risk Manag 4: , Fabbri LM, Nicolini G, Olivieri D, and Papi A. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combina- Allergy and Asthma Proceedings 143
5 tion in the treatment of asthma: Evidence and future perspectives. Expert Opin Pharmacother 9: , De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/ formoterol HFA pmdi in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 23: , Weinstein SF, Corren J, Murphy K, et al., and Study Investigators of P Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc 31: , Nathan RA, Nolte H, and Pearlman DS, and P04334 Study Investigators. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc 31: , Meltzer EO, Kuna P, Nolte H, et al., on Behalf of the P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J 39: , Cohen J, Postma DS, Douma WR, et al. Particle size matters: Diagnostics and treatment of small airways involvement in asthma. Eur Respir J 37: , Burgel PR. The role of small airways in obstructive airway diseases. Eur Respir Rev 20:23 33, e 144 March April 2012, Vol. 33, No. 2
6 Copyright of Allergy & Asthma Proceedings is the property of OceanSide Publications Inc. and its content may not be copied or ed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or articles for individual use.
Dual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationLung function and asthma control with beclomethasone and formoterol in a single inhaler
Respiratory Medicine (2009) 103, 41e49 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Lung function and asthma control with beclomethasone and formoterol in a single
More informationHigh-dose beclometasone dipropionate/ formoterol fumarate in fixed-dose combination for the treatment of asthma
654442TAR0010.1177/1753465816654442Therapeutic Advances in Respiratory DiseaseM Corradi, M Spinola research-article2016 Therapeutic Advances in Respiratory Disease Review High-dose beclometasone dipropionate/
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationHFA-CIC < HFA FP FVC, VC, FEV 1,PEF; symptoms; SABA use. HFA-CIC > DPI Bud HFA-CIC < DPI Bud HFA-CIC > DPI Bud ACT HFA-CIC =HFA-FP E8
e-table 1. Randomized controlled trials performed in asthma patients comparing outcomes after inhaled corticosteroids monotherapy administered as small-or large-particle aerosols. Treatments and relative
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More informationEnhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers Harold S. Nelson, MD, a Kenneth R. Chapman, FACP, b Stephen D. Pyke, MSc, c Malcolm
More informationEffectiveness of combined ICS/LABAs delivery devices versus concurrent ICS and LABA via separate inhalers
Effectiveness of combined ICS/LABAs delivery devices versus ICS and LABA via inhalers In summary: There is little evidence that combination products improve compliance over use of ICSA and LABA inhalers.
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationThe recent guidelines from the
...PRESENTATIONS... Adjunctive Therapy for Asthma: Treatment Options Robert A. Nathan, MD Abstract The National Heart, Lung, and Blood Institute guidelines on the diagnosis and management of asthma recommend
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationW e have shown in a previous meta-analysis of placebo
16 ASTHMA Clinical dose-response relationship of fluticasone propionate in adults with asthma M Masoli, M Weatherall, S Holt, R Beasley... See end of article for authors affiliations... Correspondence
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationImproved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone
Eur Respir J 2001; 18: 262 268 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Improved asthma control with budesonide/formoterol in a single
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationTreatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes
Patient Related Outcome Measures open access to scientific and medical research Open Access Full Text Article Review Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationThe problem with critical and non-critical inhaler errors
The problem with critical and non-critical inhaler errors Federico Lavorini MD, PhD Dept. Experimental and Clinical Medicine Careggi University Hospital Florence, Italy Presenter disclosures Federico Lavorini
More informationTreatment response according to small airway phenotypes: a real-life observational study
642635TAR0010.1177/1753465816642635Therapeutic Advances in Respiratory DiseaseK Marth, M Spinola research-article2016 Therapeutic Advances in Respiratory Disease Original Research Treatment response according
More informationMeta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
GlaxoWellcome UK, Stockley Park West, Uxbridge, Middlesex UB11 1BT Stephen Shrewsbury associate medical director Stephen Pyke section head, respiratory statistics St Peter s Hospital, Chertsey, Surrey
More informationSafety of β2-agonists in asthma
Safety of β2-agonists in asthma Sanjeeva Dissanayake IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Overview Origin of concerns Mechanistic hypotheses Large scale clinical datasets Interpretation
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationAdjustable maintenance dosing with budesonide/ formoterol or budesonide: Double-blind study $
Respiratory Medicine (2006) 100, 551 560 Adjustable maintenance dosing with budesonide/ formoterol or budesonide: Double-blind study $ W.R. Pohl a,, N. Vetter b, H. Zwick c, W. Hrubos d,1 a Grimmenstein
More informationLow-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma
Respiratory Medicine (2010) 104, 510e517 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients
More informationUS max daily dose i Food and Drug Administration [2]
APPENDIX 2 etable 1. Regulatory limits on total daily dose for asthma medications Drugs Canadian max daily dose i Health Canada [1] US max daily dose i Food and Drug Administration [2] European max daily
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationChronic obstructive pulmonary disease. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations LAUNCHING NEW STUDIES
Eur Respir J 2013; 41: 12 17 DOI: 10.1183/09031936.00207611 CopyrightßERS 2013 LAUNCHING NEW STUDIES A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations Dave Singh*, Jorg
More informationDifferences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma
Review Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma Therapeutic Advances in Respiratory Disease
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationEvidence-based recommendations or Show me the patients selected and I will tell you the results
Respiratory Medicine (2006) 100, S17 S21 Evidence-based recommendations or Show me the patients selected and I will tell you the results Leif Bjermer Department of Respiratory Medicine & Allergology, 221
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationBreakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom
Breakfast Session Prof Neil Barnes Professor of Respiratory Medicine London Chest Hospital & The Royal London Hospital United Kingdom 2 BEYOND SYMPTOMS ADDRESSING FUTURE RISK IN ASTHMA South GP CME 2013,
More informationPatient adherence to inhaled therapy A clinical perspective. Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France
Patient adherence to inhaled therapy A clinical perspective Nicolas Roche Cochin, Site Val de Grâce University Paris Descartes, Paris, France 1 Disclosures Aerocrine Almirall AstraZeneca Boehringer Ingelheim
More informationAchieving guideline-based asthma control: does the patient benefit?
Eur Respir J ; : 88 9 DOI:.8/99..97 Printed in UK all rights reserved Copyright #ERS Journals Ltd European Respiratory Journal ISSN 9-9 Achieving guideline-based asthma control: does the patient benefit?
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationDual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting -agonists with inhaled corticosteroids
Review article Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting -agonists with inhaled corticosteroids RONNANN NAEDELE-RISHA, DO PAUL DORINSKY, MD
More informationSingle maintenance and reliever therapy (SMART) of asthma: a critical appraisal
Thorax Online First, published on June 27, 2010 as 10.1136/thx.2009.128504 Review 1 Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada 2 Department
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationCopyright General Practice Airways Group Reproduction prohibited
Primary Care Respiratory Journal (2006) 15, 271 277 REVIEW Long-Acting Beta-Agonists in Adult Asthma: Evidence that these Drugs are Safe Harold S. Nelson a,b, a National Jewish Medical and Research Center,
More informationGoals and Learning Objectives
Small Airways (SAW) Symposium: Asthma Treatment Issues. New Bronchodilator for Asthma: A Patient Centric Approach for Treating Asthma Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP Thomas H. Davis
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationIntroduction E. D. BATEMAN*, V.SILINS { AND M. BOGOLUBOV {
RESPIRATORY MEDICINE (21) 95, 136 146 doi:1.153/rmed.2.18, available online at http://www.idealibrary.com on Clinical equivalence of salmeterol/fluticasone propionate in combination (5/1 mg twice daily)
More informationBudesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Eur Respir J 25; 26: 819 828 DOI: 1.1183/931936.5.2835 CopyrightßERS Journals Ltd 25 Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? C. Vogelmeier*, A. D Urzo
More informationAsthma Control: The Right Inhaler for the Right Patient
Adv Ther (2015) 32:285 292 DOI 10.1007/s12325-015-0201-9 REVIEW Asthma Control: The Right Inhaler for the Right Patient Nicola Scichilone To view enhanced content go to www.advancesintherapy.com Received:
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationDrug Class Review Controller Medications for Asthma
Drug Class Review Controller Medications for Asthma Preliminary Scan Report #1 April 2013 Last Report: April 2011 The purpose of reports is to make available information regarding the comparative clinical
More informationEfficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler
Respiratory Medicine (2011) 105, 674e682 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Efficacy and safety of fluticasone and formoterol in a single pressurized metered
More informationDr Christopher Worsnop
Dr Christopher Worsnop Respiratory & Sleep Physician Austin Hospital, Melbourne Supported by: Top Tips in Modern Asthma Management Dr Christopher Worsnop Rotorua GPCME Meeting June 2013 Speaker declaration
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationABSTRACT. . Sahori Kudo. Mitsue Ariga
https://doi.org/10.1007/s41030-018-0062-x ORIGINAL RESEARCH Evaluation of Rapid Onset of Action of ICS/LABA Combination Therapies on Respiratory Function in Asthma Patients: A Single-Center, Open-Label,
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationReport on New Patented Drugs - Alvesco
Report on New Patented Drugs - Alvesco Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive
More informationAbbreviated Class Review: Chronic Obstructive Pulmonary Disease (COPD)
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Executive summary: Month/Year of Review: February
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationKohhei Maeda 1, Masao Yamaguchi 2, Hiroyuki Nagase 2, Nobuhiro Yasuno 1, Fumio Itagaki 1,3 and Machiko Watanabe 1,3*
Maeda et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:24 https://doi.org/10.1186/s40780-018-0118-y CASE REPORT Utility and effectiveness of Symbicort Turbuhaler (oral inhalation containing
More informationRisks of Pneumonia in Patients with Asthma Taking Inhaled Corticosteroids
Risks of Pneumonia in Patients with Asthma Taking Inhaled Corticosteroids Paul M. O Byrne 1, Soren Pedersen 2, Lars-Göran Carlsson 3, Finn Radner 3, Anders Thorén 3, Stefan Peterson 3, Pierre Ernst 4,
More informationCombination Beta2-Agonist/Corticosteroid Inhalers
Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Last Review: 7/2017 Origination: 6/2014 Next Review: 7/2018 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe Journal Club: COPD Exacerbations
252 The Journal Club: COPD Exacerbations Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club The Journal Club: COPD Exacerbations Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations:
More informationEffect of AeroChamber Plus on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pmdi
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.211.424.x Effect of AeroChamber Plus on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pmdi Dave Singh, 1
More informationAlthough elucidation of the basic physiologic
Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy* James E. Fish, MD, FCCP; Elliot Israel, MD, FCCP; John
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2013, Updated September 2013 Review date: September 2016 Bulletin 176 : Choice of Inhaled Corticosteroid / Long Acting Beta 2 Agonist (ICS/LABA)
More informationShaping a Dynamic Future in Respiratory Practice. #DFResp
Shaping a Dynamic Future in Respiratory Practice #DFResp www.dynamicfuture.co.uk Inhaled Therapy in COPD: Past, Present and Future Richard Russell Chest Physician West Hampshire Integrated Respiratory
More informationPotency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler)
Respiratory Medicine (2007) 101, 610 615 Potency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler) Björn Ställberg a, Eva Pilman b, Bengt-Eric Skoogh c,, Bengt Arne Hermansson
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationCombination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid
More informationThe 3 components of evidence. Economic Analysis of Asthma Practices ...PRESENTATIONS... Based on a presentation by David A.
...PRESENTATIONS... Economic Analysis of Asthma Practices Based on a presentation by David A. Stempel, MD Presentation Summary When deciding on treatment for patients with asthma, clinicians should consider
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationKeywords : asthma ; beclometasone ; dry powder inhaler ; extrafine particles ; formoterol ; small airways
NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma Massimo Corradi 1, Henry Chrystyn 2, Borja
More informationRETRACTED ARTICLE. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? REVIEW
Naunyn-Schmiedeberg s Arch Pharmacol (2008) 378:203 215 DOI 10.1007/s00210-008-0302-y REVIEW Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Dirkje
More informationAdvancing COPD treatment strategies with evidencebased. 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy
Advancing COPD treatment strategies with evidencebased approaches 17:15 19:15 Monday 11 September 2017 ERS 2017, Milan, Italy Increasing understanding of COPD and the effect on guideline evolution. GOLD
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service
Treatment choices for patients with asthma or COPD Jo Riley Lead Nurse For Oxfordshire Respiratory Service What is the difference? Is it all about? Inhaled steroids Long acting ß2 agonists Short acting
More informationAEROSOL. Indication: /formoterol to. older with pressurized. two inhalations
CEDAC FINAL RECOMMENDATION MOMETASONE FUROATE/ FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL (Zenhale Merck Canada Inc.) Indication: Asthma Maintenanc ce (Adults, Children 12 Years or Older) Recommendation:
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationOutcome measures in asthma
S70 Thorax 2000;55(Suppl 1):S70 S74 Outcome measures in asthma N C Barnes Department of Respiratory Medicine, The London Chest Hospital, London E2 9JX, UK Introductory articles Exacerbations of asthma:
More informationFunctional Respiratory Imaging
Functional Respiratory Imaging (FRI) to assess the bioequivalence of inhaled medication Jan De Backer, MSc, PhD, MBA CEO BABE 2014 Functional Respiratory Imaging (FRI) FRI outcome parameters Added value
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationHealth technology Four treatments for patients with persistent symptoms of asthma were examined:
Adding formoterol to budesonide in moderate asthma: health economic results from the FACET study Andersson F, Stahl E, Barnes P J, Lofdahl C G, O'Byrne P M, Pauwels R A, Postma D S, Tattersfield A E, Ullman
More informationUsing Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?
Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More information